#Latest news with #daraxonrasibReuters17 hours agoBusinessReutersRoyalty Pharma to pay up to $2 billion to Revolution Medicines for cancer drugJune 24 (Reuters) - Royalty Pharma (RPRX.O), opens new tab said on Tuesday will pay up to $2 billion to Revolution Medicines (RVMD.O), opens new tab to support the companies' plans for global development and commercialization of the experimental cancer drug daraxonrasib.
Reuters17 hours agoBusinessReutersRoyalty Pharma to pay up to $2 billion to Revolution Medicines for cancer drugJune 24 (Reuters) - Royalty Pharma (RPRX.O), opens new tab said on Tuesday will pay up to $2 billion to Revolution Medicines (RVMD.O), opens new tab to support the companies' plans for global development and commercialization of the experimental cancer drug daraxonrasib.
17 hours ago
